Section Arrow
Quote
RARE.NASDAQ
- Ultragenyx Pharmaceutical
Quotes are at least 15-min delayed:2025/07/21 15:22 EDT
Regular Hours
Last
 26.512
+0.202 (+0.77%)
Day High 
26.795 
Prev. Close
26.31 
1-M High
42.37 
Volume 
2.72M 
Bid
26.51
Ask
26.53
Day Low
25.81 
Open
26.39 
1-M Low
25.995 
Market Cap 
2.49B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 31.85 
20-SMA 34.63 
50-SMA 35.51 
52-W High 60.37 
52-W Low 25.995 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.83/-4.15
Enterprise Value
2.52B
Balance Sheet
Book Value Per Share
1.53
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
560.23M
Operating Revenue Per Share
4.34
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TNFATNF Pharmaceuticals Inc.0.1176+0.0301+34.40%-- 
PMNProMIS Neurosciences1.055+0.6149+139.72%5PE
NCNANuCana plc0.0509+0.0032+6.71%-- 
SABSSAB Biotherapeutics2.7556+0.1856+7.22%-- 
RXRXRecursion Pharmaceuticals6.535+0.695+11.90%-- 
Quotes are at least 15-min delayed：2025/07/21 15:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.